Scientific article

Sécurité cardiovasculaire des antidiabétiques

Published inRevue médicale suisse, vol. 12, no. 521, p. 1084-1088
Publication date2016

Type 2 diabetes is characterized by a high risk of micro- and macro-vascular complications. Cardiovascular diseases are the leading cause of death of diabetic patients. In this context, the search for molecules decreasing cardiovascular mortality makes sense. Until the EMPA-REG OUTCOME study published late 2015, showing a reduction of cardiovascular mortality of patients treated with empagliflozin, an SGLT2 inhibitor, there was no molecule known to decrease cardiovascular mortality. The purpose of this article is to review the various existing antidiabetic molecules and their impact (positive/neutral/negative) on cardiovascular mortality.

  • Cardiovascular Diseases/etiology/mortality/prevention & control
  • Diabetes Mellitus, Type 2/complications/drug therapy
  • Humans
  • Hypoglycemic Agents/therapeutic use
  • Randomized Controlled Trials as Topic
Affiliation Not a UNIGE publication
Citation (ISO format)
ALINE ROTH, Pressl-Wenger, JORNAYVAZ, François. Sécurité cardiovasculaire des antidiabétiques. In: Revue médicale suisse, 2016, vol. 12, n° 521, p. 1084–1088.
Main files (1)
Article (Published version)
ISSN of the journal1660-9379

Technical informations

Creation09/13/2017 2:27:00 PM
First validation09/13/2017 2:27:00 PM
Update time03/15/2023 2:02:41 AM
Status update03/15/2023 2:02:40 AM
Last indexation01/17/2024 12:43:58 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack